Oral Fluoropyrimidine Improves Survival as Adjuvant Therapy in Biliary Tract Cancer

Article

The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers.

The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers, according to findings from a phase 3 trial (UMIN000011688) that were presented during the 2022 Gastrointestinal Cancers Symposium.

The 3-year overall survival (OS) rate was 77.1% (95% CI, 70.9%-82.1%) with S-1 and 67.6% (95% CI, 61.0%-73.3%) with surgery alone (HR, 0.694; 95% CI, 0.514-0.935; one-sided P = .008). Patients also had better 3-year relapse-free survival with S1 at 62.4% (95% CI, 55.6%-68.4%) and 50.9% (95% CI, 44.1%-57.2%), respectively (HR, 0.797; 95% CI, 0.613-1.035).

“Adjuvant S-1 therapy led to significantly longer survival than surgery alone on patients with resected BTC,” Masafumi Ikeda, MD, PhD, of National Cancer Center Hospital East, said during the presentation.

A total of 440 patients were enrolled onto the study, with 222 in surgery-alone arm and 218 in the S-1 arm. Those receiving S-1 were given 40 mg/m2 twice per day for 4 weeks on and 2 weeks off for a total of 4 cycles. Patients were eligible for this study if they had curatively resected biliary tract cancer, were between the ages of 20 and 80, and had a performance score of 0 or 1.

Patients receiving S-1 had a median age of 68 years compared with 70 years for surgery alone, and most patients in either group were male (74% vs 68%) and had an ECOG performance score of 0 (88% vs 87%). The primary tumor site was most likely extrahepatic (57% vs 55%), followed by ampulla of vater (17% vs 16%), gallbladder (14% vs 15%), and intrahepatic (12% vs 14%) in the S-1 and surgery-alone arms, respectively.

Most patients in the S-1 and surgery groups had a resection status of R0 (86% vs 85%, respectively) and stage II disease (58% vs 59%), followed by stage III (17% vs 17%), stage I (16% vs 16%), and stage IV (9% vs 8%). Most patients had no lymph node involvement (N0; 61% vs 59%).

OS by subgroup analysis mostly favored S-1 compared with surgery alone, including those with ECOG performance scores of 0 (0.70; 95% CI, 0.51-0.97; P = .0632) and 1 (0.85; 95% CI, 0.39-1.85) as well as those with extrahepatic (0.80; 95% CI, 0.54-1.17; P = .5344), ampulla of vater (0.49; 95% CI, 0.22-1.12; P = .3041), gallbladder (0.64; 95% CI, 0.30-1.35), and intrahepatic (0.75; 95% CI, 0.30-1.89; P = .5939) primary tumor sites.

The most common grade 3 adverse effects (AEs) in the S-1 arm was neutrophil decrease (14%) which occurred in only 1% of the surgery-alone arm. Other common grade 3 AEs were anemia (4% vs 1%), white blood cell decrease (3% vs less than 1%), aspartate aminotransferase increase (3% vs <1%), and diarrhea (3% vs 0%).

Reference

  1. Ikeda M, Nakachi K, Konishi M, et al. Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT). J Clin Oncol. 2022;40(suppl 4):382. doi:10.1200/JCO.2022.40.4_suppl.382
Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center